Numerous studies have shown that racial health disparities in gastroenterology and hepatology, but little is known about its effect on pancreatic head carcinoma (PHC). The aim of the present study was to determine whether racial disparities in the overall survival (OS) and cancer-specific survival (CSS) rates exist among US patients with PHC. The SEER database was searched for US residents who had been diagnosed with PHC from 2007 to 2015. The outcomes for 9724 Hispanic white (HW) patients and their non-Hispanic white (NHW) counterparts were compared using Kaplan-Meier survival and Cox regression analyses. We found that race affected both OS and CSS. The 5-year OS rate was worse for HW patients (45.9%) than for NHW patients (49.6%, P<0.001), as was the 5-year CSS rate (39.8% versus 44.0%, P=0.002). Race appeared to be an independent prognostic factor for PHC in the multivariate analysis, with NHW patients showing superior OS (P=0.007) and CSS (P=0.037) compared with HW patients. Subgroup analysis showed that race influenced survival among patients who received surgery, enjoyed Medicaid, and those at American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage II, but not of patients at AJCC TNM stage I, III, or IV and those who did not receive surgery or had no insurance. In short, the survival outcomes for PHC are better for NHW than HW patients. The survival advantage is more skewed towards NHW patients than HW patients with PHC, so culturally appropriate interventions, strengthened preventive services, and additional financial support should focus more on HWs.
| Published in | American Journal of Biomedical and Life Sciences (Volume 9, Issue 1) |
| DOI | 10.11648/j.ajbls.20210901.18 |
| Page(s) | 58-68 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Pancreatic Head Carcinoma, Survival Advantage, SEER, OS, CSS
| [1] | Wang W, He Y, Wu L, et al. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. Pancreatology. 2019 Dec; 19 (8): 1074-1080. doi: 10.1016/j.pan.2019.10.003. PubMed PMID: 31668841. |
| [2] | Moutinho-Ribeiro P, Coelho R, Giovannini M, et al. Pancreatic cancer screening: Still a delusion? Pancreatology. 2017 Sep - Oct; 17 (5): 754-765. doi: 10.1016/j.pan.2017.07.001. PubMed PMID: 28739291. |
| [3] | Cheon YK, Koo JK, Lee YS, et al. Elevated hemoglobin A1c levels are associated with worse survival in advanced pancreatic cancer patients with diabetes. Gut Liver. 2014 Mar; 8 (2): 205-14. doi: 10.5009/gnl.2014.8.2.205. PubMed PMID: 24672663; PubMed Central PMCID: PMCPMC3964272. |
| [4] | Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011 Apr 12; 19 (4): 456-69. doi: 10.1016/j.ccr.2011.03.009. PubMed PMID: 21481788. |
| [5] | Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11; 371 (11): 1039-49. doi: 10.1056/NEJMra1404198. PubMed PMID: 25207767. |
| [6] | Flores I, Casaletto KB, Marquine MJ, et al. Performance of Hispanics and Non-Hispanic Whites on the NIH Toolbox Cognition Battery: the roles of ethnicity and language backgrounds. Clin Neuropsychol. 2017 May; 31 (4): 783-797. doi: 10.1080/13854046.2016.1276216. PubMed PMID: 28080261; PubMed Central PMCID: PMCPMC5497573. |
| [7] | Goldman N. Will the Latino Mortality Advantage Endure? Res Aging. 2016 Apr; 38 (3): 263-82. doi: 10.1177/0164027515620242. PubMed PMID: 26966251; PubMed Central PMCID: PMCPMC4955825. |
| [8] | Arias E, Kochanek KD, Anderson RN. How Does Cause of Death Contribute to the Hispanic Mortality Advantage in the United States? NCHS Data Brief. 2015 Nov (221): 1-8. PubMed PMID: 26633554. |
| [9] | Cervantes A, Waymouth EK, Petrov MS. African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2019 Jan; 64 (1): 249-261. doi: 10.1007/s10620-018-5291-1. PubMed PMID: 30259278. |
| [10] | Gagliardi AR, Soong D, Gallinger S. Identifying Factors Influencing Pancreatic Cancer Management to Inform Quality Improvement Efforts and Future Research: A Scoping Systematic Review. Pancreas. 2016 Feb; 45 (2): 161-6. doi: 10.1097/MPA.0000000000000484. PubMed PMID: 26752254. |
| [11] | Yang J, Li Y, Liu Q, et al. Brief introduction of medical database and data mining technology in big data era. J Evid Based Med. 2020 Feb; 13 (1): 57-69. doi: 10.1111/jebm.12373. PubMed PMID: 32086994; PubMed Central PMCID: PMCPMC7065247. |
| [12] | Torgeson A, Tao R, Garrido-Laguna I, et al. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol. 2018 Dec; 9 (6): 996-1004. doi: 10.21037/jgo.2018.05.15. PubMed PMID: 30603118; PubMed Central PMCID: PMCPMC6286942. |
| [13] | Mukhija D, Nagpal SJS, Sohal DPS. Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma: A Large Population-based Study Using the SEER Database. Am J Clin Oncol. 2019 May; 42 (5): 454-458. doi: 10.1097/COC.0000000000000544. PubMed PMID: 30950860. |
| [14] | Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020 May 15; 126 (10): 2225-2249. doi: 10.1002/cncr.32802. PubMed PMID: 32162336; PubMed Central PMCID: PMCPMC7299151. |
| [15] | Yang R, Cheung MC, Byrne MM, et al. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg. 2010 Jan; 145 (1): 49-56. doi: 10.1001/archsurg.2009.244. PubMed PMID: 20083754. |
| [16] | El Nakeeb A, Roshdy S, Ask W, et al. Comparative Study between Uncinate process carcinoma and Pancreatic head carcinoma after Pancreaticodudenectomy (Clincopathological features and Surgical outcomes). Hepato-Gastroenterol. 2014 Sep; 61 (134): 1748-1755. PubMed PMID: WOS:000341170900046; English. |
| [17] | Ashktorab H, Kupfer SS, Brim H, et al. Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology. 2017 Oct; 153 (4): 910-923. doi: 10.1053/j.gastro.2017.08.018. PubMed PMID: 28807841; PubMed Central PMCID: PMCPMC5623134. |
| [18] | McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21; 24 (43): 4846-4861. doi: 10.3748/wjg.v24.i43.4846. PubMed PMID: 30487695; PubMed Central PMCID: PMCPMC6250924. |
| [19] | Molina G, Clancy TE, Tsai TC, et al. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. Ann Surg Oncol. 2020 Jul 10. doi: 10.1245/s10434-020-08717-x. PubMed PMID: 32651695. |
| [20] | Nipp R, Tramontano AC, Kong CY, et al. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018 Feb; 7 (2): 525-535. doi: 10.1002/cam4.1277. PubMed PMID: 29322643; PubMed Central PMCID: PMCPMC5806100. |
| [21] | Loehrer AP, Chang DC, Hutter MM, et al. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? J Am Coll Surg. 2015 Dec; 221 (6): 1015-22. doi: 10.1016/j.jamcollsurg.2015.09.010. PubMed PMID: 26611798; PubMed Central PMCID: PMCPMC4662773. |
| [22] | Abraham A, Al-Refaie WB, Parsons HM, et al. Disparities in pancreas cancer care. Ann Surg Oncol. 2013 Jun; 20 (6): 2078-87. doi: 10.1245/s10434-012-2843-z. PubMed PMID: 23579872. |
| [23] | Shapiro M, Chen Q, Huang Q, et al. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. JAMA Surg. 2016 Apr; 151 (4): 338-45. doi: 10.1001/jamasurg.2015.4239. PubMed PMID: 26581025. |
| [24] | Miller KD, Goding Sauer A, Ortiz AP, et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018 Nov; 68 (6): 425-445. doi: 10.3322/caac.21494. PubMed PMID: 30285281. |
| [25] | Nordby T, Hugenschmidt H, Fagerland MW, et al. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol. 2013 Jun; 39 (6): 559-66. doi: 10.1016/j.ejso.2013.02.020. PubMed PMID: 23498362. |
| [26] | Ziebland S, Chapple A, Evans J. Barriers to shared decisions in the most serious of cancers: a qualitative study of patients with pancreatic cancer treated in the UK. Health Expect. 2015 Dec; 18 (6): 3302-12. doi: 10.1111/hex.12319. PubMed PMID: 25496598; PubMed Central PMCID: PMCPMC5810685. |
| [27] | Sohal DPS, Willingham FF, Falconi M, et al. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. Am Soc Clin Oncol Educ Book. 2017; 37: 301-310. doi: 10.14694/EDBK_175222 10.1200/EDBK_175222. PubMed PMID: 28561672. |
| [28] | Sanford NN, Aguilera TA, Folkert MR, et al. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2019 Nov 1; 17 (11): 1292-1300. doi: 10.6004/jnccn.2019.7322. PubMed PMID: 31693987. |
| [29] | Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018 Jun 1; 153 (6): 588-589. doi: 10.1001/jamasurg.2018.0501. PubMed PMID: 29617544. |
| [30] | Sun H, Ma H, Hong G, et al. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Sci Rep. 2014 Oct 23; 4: 6747. doi: 10.1038/srep06747. PubMed PMID: 25339498; PubMed Central PMCID: PMCPMC5381379. |
APA Style
Hongyu Yu, Chengzhuo Li, Qihui Wu, Jukun Su, Ankang Liu, et al. (2021). Survival Advantage of Non-hispanic White Patients with Pancreatic Head Carcinoma: A Population-based Study. American Journal of Biomedical and Life Sciences, 9(1), 58-68. https://doi.org/10.11648/j.ajbls.20210901.18
ACS Style
Hongyu Yu; Chengzhuo Li; Qihui Wu; Jukun Su; Ankang Liu, et al. Survival Advantage of Non-hispanic White Patients with Pancreatic Head Carcinoma: A Population-based Study. Am. J. Biomed. Life Sci. 2021, 9(1), 58-68. doi: 10.11648/j.ajbls.20210901.18
AMA Style
Hongyu Yu, Chengzhuo Li, Qihui Wu, Jukun Su, Ankang Liu, et al. Survival Advantage of Non-hispanic White Patients with Pancreatic Head Carcinoma: A Population-based Study. Am J Biomed Life Sci. 2021;9(1):58-68. doi: 10.11648/j.ajbls.20210901.18
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbls.20210901.18,
author = {Hongyu Yu and Chengzhuo Li and Qihui Wu and Jukun Su and Ankang Liu and Qiqi Ke and Qiaohong Yang},
title = {Survival Advantage of Non-hispanic White Patients with Pancreatic Head Carcinoma: A Population-based Study},
journal = {American Journal of Biomedical and Life Sciences},
volume = {9},
number = {1},
pages = {58-68},
doi = {10.11648/j.ajbls.20210901.18},
url = {https://doi.org/10.11648/j.ajbls.20210901.18},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210901.18},
abstract = {Numerous studies have shown that racial health disparities in gastroenterology and hepatology, but little is known about its effect on pancreatic head carcinoma (PHC). The aim of the present study was to determine whether racial disparities in the overall survival (OS) and cancer-specific survival (CSS) rates exist among US patients with PHC. The SEER database was searched for US residents who had been diagnosed with PHC from 2007 to 2015. The outcomes for 9724 Hispanic white (HW) patients and their non-Hispanic white (NHW) counterparts were compared using Kaplan-Meier survival and Cox regression analyses. We found that race affected both OS and CSS. The 5-year OS rate was worse for HW patients (45.9%) than for NHW patients (49.6%, P<0.001), as was the 5-year CSS rate (39.8% versus 44.0%, P=0.002). Race appeared to be an independent prognostic factor for PHC in the multivariate analysis, with NHW patients showing superior OS (P=0.007) and CSS (P=0.037) compared with HW patients. Subgroup analysis showed that race influenced survival among patients who received surgery, enjoyed Medicaid, and those at American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage II, but not of patients at AJCC TNM stage I, III, or IV and those who did not receive surgery or had no insurance. In short, the survival outcomes for PHC are better for NHW than HW patients. The survival advantage is more skewed towards NHW patients than HW patients with PHC, so culturally appropriate interventions, strengthened preventive services, and additional financial support should focus more on HWs.},
year = {2021}
}
TY - JOUR T1 - Survival Advantage of Non-hispanic White Patients with Pancreatic Head Carcinoma: A Population-based Study AU - Hongyu Yu AU - Chengzhuo Li AU - Qihui Wu AU - Jukun Su AU - Ankang Liu AU - Qiqi Ke AU - Qiaohong Yang Y1 - 2021/02/02 PY - 2021 N1 - https://doi.org/10.11648/j.ajbls.20210901.18 DO - 10.11648/j.ajbls.20210901.18 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 58 EP - 68 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20210901.18 AB - Numerous studies have shown that racial health disparities in gastroenterology and hepatology, but little is known about its effect on pancreatic head carcinoma (PHC). The aim of the present study was to determine whether racial disparities in the overall survival (OS) and cancer-specific survival (CSS) rates exist among US patients with PHC. The SEER database was searched for US residents who had been diagnosed with PHC from 2007 to 2015. The outcomes for 9724 Hispanic white (HW) patients and their non-Hispanic white (NHW) counterparts were compared using Kaplan-Meier survival and Cox regression analyses. We found that race affected both OS and CSS. The 5-year OS rate was worse for HW patients (45.9%) than for NHW patients (49.6%, P<0.001), as was the 5-year CSS rate (39.8% versus 44.0%, P=0.002). Race appeared to be an independent prognostic factor for PHC in the multivariate analysis, with NHW patients showing superior OS (P=0.007) and CSS (P=0.037) compared with HW patients. Subgroup analysis showed that race influenced survival among patients who received surgery, enjoyed Medicaid, and those at American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage II, but not of patients at AJCC TNM stage I, III, or IV and those who did not receive surgery or had no insurance. In short, the survival outcomes for PHC are better for NHW than HW patients. The survival advantage is more skewed towards NHW patients than HW patients with PHC, so culturally appropriate interventions, strengthened preventive services, and additional financial support should focus more on HWs. VL - 9 IS - 1 ER -
Information
Email: